Pharnext : To Attend November Investors Conferences
November 02, 2017 at 12:55 pm EDT
Share
DGAP-News: Pharnext S.A. / Key word(s): Conference
Pharnext To Attend November Investors Conferences
02.11.2017 / 17:48
The issuer is solely responsible for the content of this announcement.
Pharnext To Attend November Investors Conferences
PARIS, France, 5:45pm, November 2nd (CET) - Pharnext SA (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that senior management will be attending the following conferences taking place in November 2017 throughout Europe.
BIO-Europe(R) 2017[1], on November 6-8, 2017 at CityCube Berlin, Berlin, Germany.
Jefferies 2017 London Healthcare Conference[2] on November 16, 2017 in London, United Kingdom.
Actionaria[3], Individuals shareholders exhibition on November 23-24, 2017 at Palais des Congrès, Paris, France. Corporate Overview Presentation: during "Facing the leaders" on
November 23, from 3:45pm to 4:00pm CET. Speaker : Mr. Olivier Legrand, Pharnext.
Geneva European Midcap Event[4]on November 28, 2017 in Geneva, Switzerland.
If you are interested in meeting the Pharnext management team during either of these events or if you need more information about Pharnext's participation, please send an email to investors@pharnext.com
About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY(TM). The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG(TM) offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).
For more information, visit www.pharnext.com
CONTACTS:
Pharnext
René GoedKoop
Chief Medical Officer medical@pharnext.com
+33 (0)1 41 09 22 30
Investor Relations (USA)
Stern Investor Relations, Inc.
Matthew Shinseki matthew@sternir.com
+1 212 362 1200
Investor Relations (Europa)
MC Services AG
Anne Hennecke anne.hennecke@mc-services.eu
+49 211 529252 22
Media Relations (USA)
RooneyPartners
Marion Janic mjanic@rooneyco.com
+1 212 223 4017
Media Relations (Europa)
ALIZE RP
Caroline Carmagnol
Margaux Pronost pharnext@alizerp.com
+33 (0)1 44 54 36 64
02.11.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Pharnext SCA specializes in the development of drugs based on PleotherapyTM for the treatment of severe, rare and common neurological diseases (including Alzheimer, Charcot-Marie Tooth disease, Parkinson's and amyotrophic lateral sclerosis). The company keeps creating new treatments by combining, at very low doses, molecules that are already tested for other diseases.
The group has a portfolio of 2 products in clinical development: PXT3003 (treatment of the orphan disease Charcot-Marie-Tooth type 1A) and PXT864 (Alzheimer's disease treatment).
PHARNEXT SCA 
